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Abstract
Patients with community-acquired pneumonia (CAP) in the hospital
setting exhibit markedly abnormal levels of various biomarkers of
infection, inflammation and coagulation. CAP is a well charac-
terized disease, relatively homogeneous and amenable to manage-
ment according to defined protocols. Hence, this group of patients
represents an opportunity to investigate further these biomarkers
as a means of determining disease severity and identifying
candidates for new therapies. Changes in biomarker levels during
the course of disease may enable physicians to identify those
patients who are most at risk for deterioration and progression
toward severe CAP and who are in greatest need of early inter-
vention. Subgroup analysis of the placebo-controlled OPTIMIST
trial of tifacogin in severe sepsis revealed a trend toward benefit in
patients with procalcitonin levels of 2 ng/ml or greater and in those
with high baseline markers of activated coagulation. Biomarker
studies are being undertaken as part of the ongoing CAPTIVATE
study. This study includes patients with severe CAP and will
compare the efficacy and safety of recombinant tissue factor
pathway inhibitor (tifacogin) versus placebo. In the future it may
also be possible to use genomic markers to identify patients at
greatest risk for deterioration or complications.
Introduction
Community-acquired pneumonia (CAP) accounts for 1.3
million hospitalizations each year in the USA, at an annual
cost of $8.4 billion [1]. The average duration of hospitaliza-
tion for CAP managed on the ward is 6 days, at a cost of
$7,500. If intensive care unit (ICU) admission (for severe
CAP) is required, then the stay increases to 23 days, at a
cost of $21,144. The average cost for managing pneumonia
in the UK was estimated at £100 per episode, as compared
with £1,700 to £5,100 for hospitalized (severe CAP) patients.
Hospitalization accounted for 87% of the total annual cost
[2,3].
Although CAP is very common, it remains a common cause of
death. Hence, severe CAP has been reported to be the
largest single cause of mortality from infectious diseases in
industrialized countries [4]. For example, a study conducted
in the USA compared outcomes in more than 150,000
patients aged over 65 years who were hospitalized for CAP
with those in 800,000 control individuals matched for age,
sex and race who were admitted to hospital for conditions
other than pneumonia [4]. The in-hospital mortality rate among
CAP patients was significantly higher, at 11%, than that in
non-CAP patients (5.5%; P < 0.001). Surprisingly, the 1-year
mortality rate among CAP patients remained significantly
higher than that in control individuals (41% versus 29%;
P < 0.001). Thus, mortality rates in patients with severe CAP
remain high and are discussed in detail elsewhere in this
supplement [5]. The factors that underlie the poor short-term
and long-term survival rates in patients with CAP and severe
CAP are not yet completely understood. However, aspects of
the pathophysiology of the disease, reflected in some of the
recently described biomarkers and genomic markers, may
contribute to increased understanding.
Hence, in addition to being an infectious disease, severe
CAP elicits major systemic responses that could also allow
this pathology to be classified as inflammatory (indicated by
systemic release of large amounts of proinflammatory
cytokines and lipid mediators) and as a disease of haemo-
stasis disorders (demonstrated by increased coagulation) [4].
As such, this review focuses primarily on biomarkers that may
indicate susceptibility to CAP or severity of the two systemic
responses (inflammation and coagulation). It also discusses
the potential for genetic markers to indicate increased
individual patient susceptibility to CAP.
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Any review of biomarkers should keep in mind the intended
purpose of the marker and the setting in which it is to be
used. Among potential uses of biomarkers in clinical research,
the following can be distinguished: to identify patients
suitable for enrolment in a trial based on the nature and
severity of their disease; to elucidate a drug’s mechanism of
action; to demonstrate that a drug is having a particular
biological effect; to establish which groups of patients within
a trial population exhibit the greatest beneficial response or
detrimental response; and, possibly, as a surrogate for
outcome.
In the specific clinical setting of patients suspected of having
CAP, we can envisage using biomarkers as an aid to identify
the presence or absence of infection; to establish disease
severity, risk for progression and death, and hence the need
for hospitalization or admission to the ICU; to select those
patients who are most likely to benefit from a specific drug or
other intervention, especially those at high risk for mortality;
and to monitor the efficacy of therapy and determine the need
for escalation or de-escalation of treatment.
Clinical stratification of risk
Several risk stratification schemes for CAP patients have
been developed and validated [5]. These include the
Pneumonia Severity Index (PSI), which is based on 20
variables; the CURB-65 scale (incorporating Confusion,
Urea, Respiratory Rate, Blood pressure, and age over 65
years; the simpler CRB-65 scale; and most recently the
combined Infectious Diseases Society of America/American
Thoracic Society guidelines for the management of CAP,
which rely on the identification of major and minor clinical and
laboratory criteria to determine whether patients should be
admitted to the ICU [6].
A recent retrospective study of specificity and sensitivity in
419 patients with CAP [7] showed that the CURB-65 score
outperformed the Standardized Early Warning Score and the
systemic inflammatory response syndrome criteria as a
predictor of mortality. The authors concluded that CURB-65
may be preferred over systemic inflammatory response
syndrome criteria and Standardized Early Warning Score in
the initial prognostic assessment of patients with CAP.
A larger prospective study conducted in 1,016 patients with
CAP [8] investigated the ability of CURB-65, CRB-65 and
PSI to predict 30-day mortality. The area under the receiver
operating curve (AUC) for CURB-65 (0.733) was very similar
to that for PSI (0.736) and slightly higher than that for CRB-
65 (0.694). All three systems had high negative predictive
values but relatively low positive predictive values. CURB-65
can be recommended because of its simplicity and ability to
identify patients at low risk.
As a generalization, these clinic-based systems, although
relatively good at quickly selecting low-risk patients who can
be managed as outpatients, have not been particularly effec-
tive at identifying patients at highest risk who are most likely
to benefit from entry into trials of novel therapies. As such,
physicians still lack effective means to establish disease
severity, likelihood of deterioration, requirement for ICU
admission and suitability for specific treatments. It is within
this context that the search for reliable biomarkers assumes
importance.
Biomarkers as prognostic factors
Procalcitonin and C-reactive protein
Muller and coworkers [9] recently reported a study including
545 patients with radiographic findings suggestive of CAP
who were admitted to the emergency department. Subse-
quently, 373 patients were confirmed as having CAP and
were included for determination of the best biological
diagnosis and prognostic biomarker in this context. Procalci-
tonin (PCT) was clearly more accurate in differentiating CAP
from other conditions than was C-reactive protein (CRP) or
total leucocyte count. The AUCs for the three markers were
0.88, 0.73 and 0.69, respectively. In contrast, all clinical signs
that are routinely used to diagnose CAP, such as fever,
sputum and chest auscultation, appeared to be very poor
indicators of CAP (AUC between 0.3 and 0.6). In this study,
PCT was also a better predictor of bacteraemia than the
other markers. Moreover, there was a significant relationship
between PSI category and PCT levels. In contrast, neither
CRP nor leucocyte count exhibited any correlation with the
PSI category.
Among patients in the highest PSI category (class V), the
mean PCT was markedly elevated. Unexpectedly, however,
many patients within this high-risk group had a normal level of
PCT. Data from the University of Pittsburgh Genetic Inflam-
matory Mediator Study (GenIMS) [10], which is one of
several recent attempts to gather information on large cohorts
of CAP patients, provide further information on this group of
patients. More than 2,000 patients with clinically and radio-
graphically diagnosed CAP were enrolled in this study.
Among them, 1,651 (who became the study cohort) had their
PCT level measured on day 1. Even among patients classified
as PSI group IV or V, those whose PCT levels were low at the
outset (<0.1 ng/ml) had negligible 30-day and 90-day
mortality rates (Figure 1). They also had a relatively short
length of hospital stay and little likelihood of requiring
admission to the ICU. This was also true among patients who
fell into group 3 according to the CURB-65 system. Normal
PCT is therefore an indicator of low risk even when scores
based on clinical factors are high. Incorporation of the PCT
biomarker would enhance the prognostic value of these
systems of risk stratification.
Other prohormones
A multicentre, prospective study conducted by the German
CAPNETZ group investigated the ability of several pro-
hormones to predict disease severity and risk for death inPage 3 of 7
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589 patients with proven CAP [11]. As previously reported,
PCT was of significant but modest prognostic value. In accor-
dance with the data from the Pittsburgh study described
above [10], 30-day survival was more than 98% among
patients with a PCT level under 0.15 ng/ml. Pro-atrial natriuretic
peptide (proANP), using a cut off of 116 pmol/l, had a similar
prognostic significance for mortality. The most predictive
factor was pro-vasopressin (proAVP); 98% of patients with a
proAVP value of 28.8 pmol/l or less survived, as compared
with 83% of patients with higher values (Figure 2).
Although CRP exhibited no relationship with CRB-65 score,
levels of PCT, proANP and proAVP increased with disease
severity [11]. Patients who died within 28 days had median
proANP and proAVP levels at baseline that were significantly
higher than those in patients who survived. In multivariate
analysis, along with co-existing illness and CRB-65 score,
raised proANP and proAVP were the strongest predictors of
mortality. These biomarkers therefore appear to have
potential in the risk stratification of patients with CAP.
A similar degree of predictive value has been demonstrated
for another prohormone, namely pro-adrenomedullin (proADM).
In a prospective study conducted in 302 patients admitted to
the emergency department with CAP [12], proADM levels
increased with higher PSI score, and proADM levels on
admission were found to have been higher in patients who
subsequently died than in survivors.
PCT is the marker that has been most widely investigated
and most frequently used in CAP. It has also become the
marker of choice for distinguishing between infectious and
noninfectious aetiologies. However, several other pro-
hormones appear to have a similar ability to discriminate
disease severity.
Markers of inflammation
The Health Aging and Body Composition study [13] has
been prospectively gathering longitudinal data in a cohort of
3,075 initially healthy people aged between 65 and 74 years.
Over 6.5 years of follow up, 162 experienced an episode of
CAP severe enough to require hospitalization. Risk was
greatest among people whose baseline plasma levels of both
tumour necrosis factor (TNF)-α and IL-6 were in the highest
tertile (adjusted risk 2.8). Furthermore, people whose marker
levels were in the highest third for either TNF-α or IL-6 had
intermediate risk (adjusted risk 1.6); and those whose levels
were below the third tertile on both markers were least likely
to develop CAP. This pattern was unaltered when people
were stratified by potentially confounding factors such as
smoking history, reduced lung function, and diabetes or other
co-morbid conditions. These two cytokines were previously
associated with severity of sepsis. Hence, it is interesting
that, among the 1,886 patients initially enrolled in the
GenIMS study of CAP, the 583 patients who developed
severe sepsis (31% of the cohort) had a higher death rate
than those who did not [14]. At 90 days, the mortality rates
were 25% versus 5%; and at 1 year they were 35% versus
less than 20%.
The relationship of inflammatory markers in sepsis and its
outcome is also interesting [14]. Throughout the first week of
hospitalization, the mean level of the proinflammatory cytokine
IL-6 was significantly higher in patients who developed
severe sepsis and died than in patients who developed
sepsis but survived. Mean IL-6 levels were lowest in patients
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Figure 1
PCT level and PSI prognostic value. Low levels (<0.1 mg/ml) of PCT at
baseline are predictive of survival, even in PSI group IV and V patients,
although the distinction is less defined in PSI group V patients.
Reproduced with permission from Huang and coworkers [10]. PCT,
procalcitonin; PSI, Pneumonia Severity Index.
Figure 2
Prognostic value of ProANP and ProAVP in CAP. ProANP and proAVP
at levels below 116 pmol/l and 28.8 pmol/l, respectively, are predictive
of survival in CAP patients over a 30-day period. Reproduced with
permission from Krüger and coworkers [11]. CAP, community-acquired
pneumonia; proANP, pro-atrial natriuretic peptide; proAVP, pro-
vasopressin.who did not develop sepsis at all. The pattern was similar for
the anti-inflammatory cytokine IL-10. However, although levels
of this cytokine were clearly high in patients who subse-
quently died from sepsis, the difference between survivors of
sepsis and those not developing the condition was less clear
cut.
The close association of these cytokines with poor outcome
is also evident in the hazard ratios (HRs) calculated in this
study [14]. Among patients in the highest tertile for both IL-6
and IL-10, the HR for death from sepsis was 20.5. In those
with medium levels of both markers the HR was around 5,
and patients with low levels of both IL-6 and IL-10 at
admission were at very low risk for developing severe sepsis
and had excellent prospects for survival. The HRs based on
high cytokine levels were far higher than the HRs associated
with older age (Figure 3). The GenIMS study also provided
clear evidence of the prognostic significance of elevated IL-6
and IL-10 measured at the time of hospital discharge [15].
Death rates in the subsequent year reached 20% for those
with high IL-6 levels and 15% for those with high levels of
IL-10. For patients with low levels of these cytokines at
discharge, the likelihood of dying was approximately one-third
lower.
Markers of coagulation
Our understanding of the potential prognostic value of coagu-
lation markers is hampered by the paucity of large studies.
One study that contributes useful data is that by Querol-
Ribelles and coworkers [16], who prospectively investigated
the relationship between plasma D-dimer level and mortality in
302 consecutive CAP patients admitted to a single hospital.
Overall, D-dimer levels were significantly higher in patients
with severe CAP who died than in those who survived (mean
3,786 ng/ml versus 1,609 ng/ml; P < 0.0001).
Among patients in the PSI V category (those with the most
severe disease clinically), the probability of death rose
steadily from 8% when baseline D-dimer levels were below
500 ng/ml to 77% when they exceeded 5,000 ng/ml. Among
patients in PSI category IV, mortality remained minimal until
D-dimer levels exceeded 2,000 ng/ml, at which point the
death rate was 10%. Mortality rose to 21% when D-dimer
levels reached 5,000 ng/ml and greater (Figure 4). Raised D-
dimer levels also predicted need for mechanical ventilation,
itself a marker for severe CAP.
Other coagulation markers under investigation as having
potential utility as biomarkers for indicating the presence of
coagulatory disorders associated with severe CAP include
prothrombin fragment 1.2, thrombin-antithrombin complexes
and fibrinogen.
Genetic markers of susceptibility and prognosis
Links have been established between many genetic poly-
morphisms and risk for severe sepsis and CAP. These links
can be divided into those that affect genes involved in
pathogen detection (such as those of Toll-like receptors or
CD-14), those influencing inflammatory processes (genes
involving the TNF locus or IL-6, IL-10 and IL-18, for example),
and those related to coagulation, such as plasminogen
activator inhibitor-1, factor V, protein C and fibrinogen.
Patients with single nucleotide polymorphisms (SNPs)
associated with high levels of TNF are at enhanced risk for
developing septic shock. Waterer and coworkers [17]
investigated 343 patients admitted to a single hospital
system with CAP, 30 of whom had septic shock, and deter-
mined prospectively the presence or absence of SNPs at the
heat shock protein 70-2 and lymphotoxin-α +250 loci.
Patients homozygous for AA heat shock protein 70-2 had a
20% chance of developing septic shock, a relative risk of 3.5
compared with patients without an SNP at this site. Presence
of the lymphotoxin-α +250 AA genotype was associated with
a 15% risk for developing septic shock and a relative risk of
2.7. This study provides clear evidence of the susceptibility
conferred by variations in the genes encoding these
important immunomodulatory proteins.
In the GenIMS study described above, high levels of IL-10 in
CAP patients were linked to increased risk of death from
sepsis. Work relevant to the genetics underlying this associa-
tion was carried out by a Canadian group who studied a
cohort of 550 Caucasian patients with sepsis, 158 of whom
Critical Care    Vol 12 Suppl 6 Mira et al.
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Figure 3
Plasma cytokine concentrations and CAP severity and mortality.
Results are from a Cox proportional hazards model for mortality. Points
estimates are shown along with their 95% confidence intervals. Age
(increase in age of 10 years), co-morbidity (CCI) and high levels of
cytokines (IL-6 or IL-10) are associated with death. The combination of
high concentrations of IL-6 and IL-10 was associated with a 20 times
increased risk for death. Reproduced with permission from Kellum and
coworkers [14]. CAP, community-acquired pneumonia; CCI, Charlson
Comorbidity Index; IL, interleukin.had pneumonia as the primary source [18]. By investigating
three SNPs in the IL-10 gene, the group identified a haplo-
type associated with increased mortality in pneumonia
patients with sepsis. Those with one or two copies of the
haplotype had a 28-day mortality of 51%, as compared with
29% in noncarriers. Carriers of the haplotype also required
greater use of vasopressors and had greater renal, hepatic
and haematological dysfunction than did noncarriers. Interest-
ingly, the risk conferred by the IL-10 haplotype was confined
to patients with sepsis related to pneumonia. Presence of the
SNPs did not predict higher risk for mortality or organ
dysfunction in patients with sepsis of similar severity deriving
from nonpulmonary sites of infection.
Polymorphisms related to the coagulation system have also
been linked to susceptibility to development of pneumonia.
Thus, workers in Pittsburgh [19] established that the 4G/5G
polymorphism and other mutations that increase plasminogen
activator inhibitor-1 expression doubled the likelihood that
elderly white people enrolled in the Health ABC cohort would
experience an episode of CAP during a 12-year follow-up
period.
Such a finding does not define specific strategies for the
primary prevention of CAP, but it contributes to our
confidence that genetic factors that are useful in managing
CAP will be identified in years to come. With increasing
knowledge of the inherited factors that underlie expression of
molecules relevant to outcome in CAP, in the future it should
become possible to tailor the management of an individual
patient to his or her specific genotype [20].
Biomarkers and treatment decisions
Christ-Crain and colleagues [21] in Basel have pioneered the
strategy of using PCT to guide the management of CAP in
patients arriving at the emergency department. In a recent
study, 404 patients were randomized at entry to antibiotic
treatment guided by PCT or to a group in which antibiotics
were given according to standard protocols. The group in
which antibiotics were given or withheld according to the
PCT level were less likely to receive the drugs (80% versus
100%) and had a shorter duration of antibiotic therapy (5 days
versus >12 days). Moreover, use of antibiotics was more
attuned to disease severity; PCT-guided treatment resulted in
patients in the low-risk PSI groups (I to III) being treated for
4 days, whereas the standard protocol approach led them to
be treated for 12 days (as long as patients in higher severity
groups; Figure 5).
Most importantly, the intent-to-treat analysis revealed that
guiding antibiotic use by PCT was associated with the same
clinical outcome as standard protocol, which generated far
greater use of antibiotics. Confirmation of this finding is now
being sought in a prospective randomized controlled trial in
more than 1,000 patients with lower respiratory tract infec-
tions [22]; demonstrating noninferiority of the PCT-guided
approach will be the primary outcome.
Evidence of the potential benefit of PCT was also found in a
study conducted by Menendez and coworkers [23], which
suggests that the marker can be helpful in identifying the
10% to 15% of CAP patients in whom treatment will fail (a
situation associated with mortality of about 40%). Menendez
and coworkers prospectively measured CRP, PCT and
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Figure 4
Plasma D-dimer levels correlate with PSI severity and outcomes in
CAP patients. The probability of death in relationship with D-dimer
levels in PSI categories IV and V is shown. D-dimer levels correlate
well with increasing probability of death in PSI IV and V patients.
Probabilities were calculated with a logistic regression model using
PSI and D-dimer levels as independent variables. Reproduced with
permission from Querol-Ribelles and coworkers [16]. CAP,
community-acquired pneumonia; PSI, Pneumonia Severity Index.
Figure 5
PCT-guided antibiotic therapy in CAP leads to reduced time on
antibiotics and antibiotic use. (a) Percentage of patients receiving
antibiotic therapy in the control group and the procalcitonin group on
admission and during the course of the disease. (b) Cumulative
frequency distribution curve for the time to discontinuation in patients
for whom antibiotic therapy was prescribed. Patients in the
procalcitonin group were compared with those in the control group.
Reproduced with permission from Christ-Crain and coworkers [21].
AB, antibiotics.cytokines at days 1 and 3, looking for a relationship with
treatment failure defined by need of mechanical ventilation,
vasopressors or other forms of organ support. IL-6 level at
day 1 was significantly related to late treatment failure (failure
occurring after 72 hours). However, PCT was predictive of
early failure (within the first 72 hours), with a sensitivity of
57% and a specificity of 75% [23]. It may therefore have
particular value in identifying patients at high risk for disease
progression.
Subgroup analysis of the placebo-controlled OPTIMIST trial
of tifacogin in severe sepsis revealed a trend toward benefit
in patients with procalcitonin levels of 2 ng/ml or greater and
in those with high baseline markers of activated coagulation
(unpublished data). Changes in biomarkers during the course
of disease may enable us to identify those patients who are
most at risk for deterioration and in greatest need of early
intervention. Such studies are being undertaken as part of the
ongoing CAPTIVATE study of recombinant tissue factor
pathway inhibitor (tifacogin) in severe CAP.
Conclusion
The management of severe CAP would be greatly improved if
it were possible to identify, early in the course of disease,
those patients who are most likely to develop severe
complications. However, at the moment, the greatest utility of
clinical scoring systems appears to lie in detecting patients at
low risk. Several biomarkers are good options for identifying
patients who are likely to develop more severe CAP. Although
the full potential of PCT must still be established, it appears
that it may be a helpful marker of high risk, as well as having
the valuable role of distinguishing between infectious and
noninfectious aetiologies of organ dysfunction.
There are other prohormones that relate to disease severity,
and the proinflammatory cytokine IL-6 and the anti-inflam-
matory cytokine IL-10 are also clearly involved. Cytokines are
prognostic for development of CAP in healthy people, for
development of sepsis and death in hospitalized patients, and
for mortality after hospital discharge after treatment for
pneumonia and sepsis.
In considering the range of possible markers, it may be useful
to distinguish between those that reflect processes that are
clearly pathological and those that reflect aspects of the host
response to infection. None of these markers should ever be
used in isolation to make clinical decisions, and it is clear that
the role of laboratory data to help identify patients who are
likely to experience a poor outcome remains to be defined.
Nevertheless, it would appear that patients at risk, and so
eligible for trials of novel approaches, are those with PSI IV or
V disease with elevated PCT and/or D-dimer.
In the near future there may be clinically useful tools for
identifying patients with high-risk cytokine profiles and the
genotypes that underlie them. Such techniques would be
useful for deciding on both the intensity of care required for a
particular patient and the appropriateness of specific inter-
ventions. We might hypothesize, for example, that mutations
in genes that are relevant to coagulation and inflammation,
and hence to the mechanisms of action of potential adjunc-
tive therapies, will influence the degree of benefit derived
from its use. It is also plausible that differences in the patho-
physiology of sepsis arising at different sites might explain
why some adjunctive therapies could be effective in patients
with lung injury while not improving outcome in others.
Severe CAP may be considered as a systemic response to
an initially local infection. The invading pathogen stimulates
an inflammatory cytokine release, and disrupts the balance of
procoagulant and anticoagulant factors - responses that can
both be measured in the laboratory through the use of
biomarkers. An ‘ideal’ panel of tests for determining a positive
diagnosis of severe CAP perhaps should reflect the three
components of the systemic response: infection, inflammation
and haemostasis. Current clinical practice involves deter-
mining the presence of infection, usually through cultures,
Gram stain, urine antigen testing or serology, but it does not
involve routine assessment of the patient’s level of inflam-
matory response or for disorders of coagulation. Perhaps the
routine inclusion of additional tests for patients with sus-
pected severe CAP such as PCT and coagulation markers
(for example, D-dimer, prothrombin fragment 1.2 or thrombin-
antithrombin complexes) may identify patients who require
additional supportive care to address these disorders, either
through admission to ICU or through initiation of additional
treatment.
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